# High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors

> **NCT06418789** · PHASE2 · RECRUITING · sponsor: **N.N. Petrov National Medical Research Center of Oncology** · enrollment: 25 (estimated)

## Conditions studied

- Germ Cell Tumor

## Interventions

- **DRUG:** High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )

## Key facts

- **NCT ID:** NCT06418789
- **Lead sponsor:** N.N. Petrov National Medical Research Center of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2029-03-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06418789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06418789, "High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06418789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*